News Center

– Second quarter revenue increased 25% year-over-year to $81 million , driven primarily by LINZESS ® (linaclotide) U.S. net sales of $192 million and commercial margin of 60% – – Terminating licensing agreement with AstraZeneca for U.S. lesinurad franchise – – Initiated Phase III programs with

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 23, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its second quarter 2018 investor update conference call and webcast at 8:30 a.m. Eastern Time on Monday, August 6, 2018 . Individuals interested in participating in the

– Trial designed to more comprehensively evaluate the effect of linaclotide 290 mcg on bothersome abdominal symptoms, including bloating, discomfort and pain, associated with IBS-C – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 16, 2018-- Ironwood Pharmaceuticals, Inc.

– Data provide additional evidence supporting development of praliciguat as a potential treatment for diabetic nephropathy and for heart failure with preserved ejection fraction – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 23, 2018-- Ironwood Pharmaceuticals, Inc.